Tirzepatide vs Semaglutide Cost: A Path-by-Path Comparison

The short answer

For most people with commercial insurance that covers the drug, semaglutide and tirzepatide land in a similar copay range, and the manufacturer savings card (from Novo Nordisk for Wegovy/Ozempic, from Lilly for Zepbound/Mounjaro) is what pushes that copay down. For people paying cash, the newer self-pay vial programs — Lilly's single-dose Zepbound vials through LillyDirect and Novo Nordisk's self-pay Wegovy option through NovoCare Pharmacy — are the manufacturers' official low-cash-price channels and are usually far cheaper than the branded autoinjector's list price. Compounded versions have circulated at lower prices but are not FDA-approved products, and the FDA has warned about them; availability has shifted as the drugs moved off the shortage list.

This page maps every path, explains which tends to be cheaper and why, and — because prices change constantly and the sharpest risk on a cost page is a stale or invented number — sends you to each manufacturer's own savings page for the live figure rather than quoting a dollar amount that may be wrong by the time you read it.

First, separate the molecule from the brand

Tirzepatide and semaglutide are the two active ingredients. Each is sold under two brand names with different FDA-approved uses, and the approved use is what unlocks — or blocks — insurance coverage. Tirzepatide is sold as Zepbound (FDA-approved for chronic weight management) and Mounjaro (FDA-approved for type 2 diabetes). Semaglutide is sold as Wegovy (FDA-approved for chronic weight management) and Ozempic (FDA-approved for type 2 diabetes).

This matters for cost because the box you are prescribed changes both what insurance will pay for and which manufacturer savings program applies. The FDA prescribing information for each product states its approved indication; using a diabetes-labeled brand purely for weight loss is off-label, and off-label use is one of the most common reasons a claim is denied and you get pushed to a cash price.

So the honest version of 'tirzepatide vs semaglutide cost' is really four products across several payment paths. Comparing Zepbound to Wegovy (the two weight-management drugs) is the apples-to-apples comparison most weight-focused buyers actually want.

The five ways to pay — the real cost structure

Every price you will ever see for these drugs comes from one of five channels, and understanding them is more useful than any single dollar figure:

List price (WAC): the manufacturer's published sticker price for the branded autoinjector before any insurance or discount. Almost nobody pays this, but it anchors everything else. Lilly publishes list price information on its Zepbound coverage-and-savings page; Novo Nordisk publishes it via NovoCare.

Insured copay: what you pay when a commercial or government plan covers the drug. This can range from a modest copay to nothing, or to a high coinsurance percentage, depending entirely on your specific formulary and deductible.

Manufacturer savings card: a copay-reduction card from the maker (Lilly for Zepbound/Mounjaro, Novo Nordisk for Wegovy/Ozempic) that lowers your out-of-pocket cost — but generally only if you have commercial insurance, and never if you have Medicare, Medicaid, or another government plan.

Cash self-pay vials: the manufacturers' official low-cash-price channels for people without coverage — Lilly's single-dose Zepbound vials via LillyDirect, and Novo Nordisk's self-pay Wegovy option via NovoCare Pharmacy. These are typically well below the branded autoinjector list price.

Compounded: non-FDA-approved copies made by compounding pharmacies, historically the cheapest cash option but carrying real safety and legality caveats discussed below.

Cost paths compared, side by side

The table shows how the same two molecules behave across each payment path. It intentionally contains no invented dollar amounts — the live number for any cell lives on the manufacturer's own page, which is the only place a specific current price should come from.

Read it as a map of relative position, not a quote: it tells you which door to knock on for your situation, and roughly how the two molecules line up behind each door.

Insurance: weight coverage is the whole game

The single biggest cost swing is whether your plan covers the drug for your indication. Many commercial plans cover semaglutide and tirzepatide for type 2 diabetes far more readily than for weight management, because obesity drug coverage remains an optional and often-excluded benefit. That is why two people with the same insurer can have wildly different experiences: one is prescribed Ozempic or Mounjaro for diabetes and pays a low copay, the other is prescribed Wegovy or Zepbound for weight and finds it excluded entirely.

When a weight-management drug is covered, plans frequently attach step therapy, prior authorization, and BMI documentation requirements. The FDA label indication for the weight-management products defines who is eligible: a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Plans generally mirror those criteria and may demand documentation before approving.

Between the two molecules, insured copays are often in a similar range when both are covered on the same tier — so if your plan covers one but not the other, coverage, not the molecule, should drive your choice. Call the number on your insurance card and ask specifically whether the drug is covered for your indication, what tier it sits on, and whether prior authorization is required.

Manufacturer savings cards: the commercial-insurance lever

If you have commercial (employer or marketplace) insurance, the manufacturer savings card is usually the biggest single reduction available. Lilly operates savings programs for Zepbound and Mounjaro; Novo Nordisk operates them for Wegovy and Ozempic. Each is described on that drug's official savings page, and each publishes its own current terms and maximum monthly savings.

The universal catch: these cards almost always require commercial insurance and explicitly exclude anyone enrolled in Medicare, Medicaid, TRICARE, or any other federal or state healthcare program. If you are on Medicare — which covers a large share of menopausal and post-menopausal women — you generally cannot use the savings card, and your cost defaults to your plan's coverage or a cash path.

Savings-card terms change frequently, including whether the card helps most when your plan covers the drug versus when it does not. Because the exact dollar cap and eligibility rules shift, treat the manufacturer's savings page as the source of truth and re-check it before you fill, rather than relying on a figure someone quoted months ago.

Cash self-pay vials: the authoritative low-cash channel

For people without coverage, or whose plan excludes the drug, the manufacturers created official cash channels that sit well below the branded autoinjector list price. Lilly sells single-dose Zepbound vials through LillyDirect, its direct-to-patient pharmacy. Novo Nordisk offers a self-pay Wegovy option through NovoCare Pharmacy. Both are legitimate, FDA-approved products dispensed through licensed pharmacies — the difference from the pen is the delivery format and the cash price, not the medicine.

These programs are the closest thing to a fair cash comparison between the two molecules, because both manufacturers set the price directly rather than it flowing through a pharmacy benefit. Prices and included doses have been adjusted since launch, and Lilly has offered different cash prices for different vial strengths, so the current figure for each strength belongs on the LillyDirect and NovoCare pages, not in a static article.

One practical note: vial programs typically require you to draw and inject with a syringe rather than use a prefilled pen, which some people find less convenient. Weigh that against the cash savings, and confirm the current price and any starter-dose conditions directly on the manufacturer's page before committing.

Compounded tirzepatide and semaglutide: cheaper, but not FDA-approved

Compounded versions circulated widely and at lower cash prices when both drugs were on the FDA shortage list, because federal rules allow compounding pharmacies more latitude to make copies of drugs in shortage. As the shortages resolved, that latitude narrowed, and availability of compounded semaglutide and tirzepatide shifted accordingly.

The critical fact for cost-shoppers: compounded semaglutide and tirzepatide are not FDA-approved products. The FDA has issued warnings about unapproved and compounded GLP-1 products, including dosing errors and products sold by entities operating outside the legitimate compounding framework. A lower price does not carry the same manufacturing, purity, and dosing assurances as the FDA-approved brand or the manufacturer's own vials.

If a compounded product is being offered to you, that alone is not proof it is safe or legal for your situation. Treat a price that dramatically undercuts every legitimate channel as a reason for scrutiny, not a bargain — and prefer the FDA-approved vial programs, which now put a real low-cash option on the table through the manufacturers themselves.

So which is actually cheaper — tirzepatide or semaglutide?

Path by path, the honest answer is that the cheaper molecule is usually the one your specific situation favors, not one that is universally lower. If your commercial plan covers one and not the other, the covered one wins by a wide margin regardless of molecule. If both are covered on the same tier, insured copays tend to be comparable, so the deciding factors become clinical fit and side effects rather than price.

For cash payers, compare the two manufacturers' vial programs directly on the same day, because that is the only apples-to-apples cash comparison and both companies adjust prices. Neither molecule is guaranteed to be cheaper as a rule — the gap moves with each program update.

On Medicare or Medicaid, savings cards are off the table, so your real cost is whatever your plan covers (often diabetes-only), which frequently steers the decision toward the diabetes-approved brand your plan will actually pay for — an insurance outcome, not a molecule-versus-molecule price.

The takeaway: pick the path first, then compare the two molecules within that path. Choosing the molecule before you know your path is how people end up paying a list price no one needed to pay.

What this means specifically for women's hormonal health

Two considerations matter for women that a generic price comparison misses. First, tirzepatide (Zepbound and Mounjaro) can reduce the effectiveness of oral contraceptives — the FDA labeling advises additional precautions such as a barrier method or switching to a non-oral contraceptive around initiation and dose increases. Semaglutide does not carry this warning. If you use oral birth control, this is a real point of difference between the two molecules that no price table captures, and it may reasonably outweigh a modest cost gap.

Second, for menopausal and post-menopausal women, Medicare status frequently removes savings cards from the equation, which reshuffles the whole cost calculus toward covered-indication coverage and the cash vial programs. Weight changes around menopause are common, but neither drug is approved specifically for menopause, and eligibility still runs through the standard BMI-and-comorbidity criteria on the FDA label.

These drugs are also distinct from menopause hormone therapy such as estradiol, which is a different treatment with its own cost structure. For hormone-therapy pricing, ACOG's patient guidance and our own how-much-does pages are the right references — do not assume GLP-1 pricing logic transfers to hormone therapy.

How to price it for your own situation, step by step

Confirm the indication and brand your prescriber will write, since that determines coverage and which savings program applies. Weight management points to Zepbound or Wegovy; type 2 diabetes points to Mounjaro or Ozempic.

Call your insurer and ask three exact questions: Is this drug covered for my indication? What tier and copay? Is prior authorization or step therapy required? Get the answer for both molecules if your prescriber is open to either.

If you have commercial insurance, open the manufacturer's savings page for your drug and read the current card terms and eligibility, then confirm Medicare/Medicaid exclusions do not apply to you.

If you are uninsured or excluded from coverage, compare LillyDirect (Zepbound vials) against NovoCare Pharmacy (self-pay Wegovy) on the same day for the live cash price of your target dose.

Only after those steps compare the two molecules. By then, price is usually decided by your path, and the remaining choice is clinical — side effects, the contraceptive interaction, and your prescriber's judgment.

Getting either drug online — the legal path, and what to avoid

Both molecules are prescription-only. A legitimate telehealth route works like this: you complete a medical intake, a state-licensed prescriber evaluates whether you meet the FDA eligibility criteria (the BMI thresholds above for the weight drugs, or a diabetes diagnosis for the diabetes brands), and if appropriate, a prescription is sent to a licensed pharmacy — which may be a retail pharmacy, a manufacturer channel like LillyDirect, or NovoCare Pharmacy. There is no legal path to buy these drugs without a prescription and a prescriber evaluation.

As an information site, we do not sell or prescribe anything. The useful action here is to compare telehealth providers licensed in your state and confirm they route you through a real prescriber consult and a licensed pharmacy — not a checkout that ships a vial with no evaluation.

Avoid any seller offering tirzepatide or semaglutide with no prescription, no medical questions, prices that undercut every legitimate channel, or shipping from overseas. Those are the hallmarks of counterfeit and unapproved products the FDA has warned about, and the money you save is not worth an unverified injectable.

Frequently asked questions

Is tirzepatide or semaglutide cheaper overall?

Neither is universally cheaper. The payment path decides it: whichever molecule your commercial plan covers wins by a wide margin, and when both are covered on the same tier, insured copays are usually comparable. For cash payers, compare Lilly's Zepbound vials and Novo Nordisk's self-pay Wegovy on the same day, because both manufacturers adjust prices.

Why does the same drug cost so differently for different people?

Because five separate channels set the price: list price, insured copay, manufacturer savings card, cash self-pay vials, and compounded. Whether your plan covers the drug for your indication — and whether you qualify for a savings card — moves your cost far more than the choice between tirzepatide and semaglutide.

Can I use a manufacturer savings card on Medicare?

Generally no. The Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) savings cards typically require commercial insurance and explicitly exclude Medicare, Medicaid, TRICARE, and other government programs. If you are on Medicare, your cost usually defaults to your plan's coverage or a cash path. Check the drug's savings page for current terms.

Are compounded semaglutide and tirzepatide a safe way to save money?

Compounded versions are not FDA-approved products, and the FDA has warned about unapproved and compounded GLP-1 products. Availability shifted as the drugs left shortage status. A much lower price does not carry the same purity and dosing assurances as the approved brand or the manufacturers' own vial programs, which are now a legitimate low-cash option.

Do the diabetes brands cost less than the weight-loss brands?

Insurance coverage, not the label, drives this. Many plans cover Ozempic and Mounjaro for type 2 diabetes more readily than they cover Wegovy or Zepbound for weight, so a covered diabetes prescription can cost far less out of pocket. But using a diabetes brand for weight alone is off-label and is a common reason claims are denied.

Does it matter for women which molecule I choose?

Yes, beyond price. Tirzepatide (Zepbound, Mounjaro) can reduce oral contraceptive effectiveness, per FDA labeling, and advises added precautions around starting and dose increases; semaglutide carries no such warning. If you use oral birth control, that difference may reasonably outweigh a small cost gap.

What are the manufacturers' official cash channels?

Lilly sells single-dose Zepbound vials through LillyDirect, and Novo Nordisk offers a self-pay Wegovy option through NovoCare Pharmacy. Both dispense FDA-approved product through licensed pharmacies at cash prices below the branded autoinjector list price. Confirm the current price for your dose directly on those pages, since figures change.

Can I buy tirzepatide or semaglutide online without a prescription?

No. Both are prescription-only. A legitimate telehealth path requires a medical intake, evaluation by a state-licensed prescriber against FDA eligibility criteria, and dispensing by a licensed pharmacy. Any seller offering these drugs with no prescription or medical questions is a warning sign of counterfeit or unapproved product.

Primary sources

1. FDA Prescribing Information, Zepbound (tirzepatide) injection
2. FDA Prescribing Information, Wegovy (semaglutide) injection
3. FDA Prescribing Information, Mounjaro (tirzepatide) injection
4. FDA Prescribing Information, Ozempic (semaglutide) injection
5. FDA Drugs@FDA approved-drug database
6. Lilly, Zepbound coverage & savings
7. Novo Nordisk, Save on Wegovy
8. Novo Nordisk, Save on Ozempic
9. Lilly, Mounjaro savings & resources
10. NovoCare, Wegovy cost & coverage
11. NovoCare, Ozempic cost & coverage
12. NIDDK (NIH), Prescription Medications to Treat Overweight & Obesity
13. ACOG, Hormone Therapy for Menopause (patient FAQ)